Drugs / Emodepside
Emodepside
also known as
BAY 44-4400 · Emodepsida · Emodepside component of procox · Emodepside component of profender · PF 1022-221
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06412926 | May → Aug 2024 | intestinal helminthiasis, onchocerciasis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03383614 | Nov 2017 → Oct 2018 | filariasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 1 | NCT03383523 | Oct 2017 → Mar 2018 | filariasis | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 1 | NCT02661178 | Dec 2015 → Mar 2017 | — | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT07258173 | May → Sep 2026 overdue | trichuriasis | Jennifer Keiser | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06373835 | May → Sep 2024 | strongyloidiasis | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
| Phase 2 | NCT05538767 | Sep 2022 → Apr 2023 | hookworm infectious disease | Jennifer Keiser | Completed | Met primary |
| Phase 2 | NCT05180461 | Aug 2021 → Sep 2026 overdue | onchocerciasis | Drugs for Neglected Diseases | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05017194 | Aug → Dec 2021 | hookworm infectious disease, trichuriasis | Jennifer Keiser | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06800248 | Sep 2026 → Apr 2027 expected | ascariasis, hookworm infectious disease, trichuriasis | Swiss Tropical & Public Health Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06736691 | Nov 2025 → Jul 2026 | ascariasis, hookworm infectious disease, trichuriasis | Swiss Tropical & Public Health Institute | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emodepside | “Single Doses of 2 Formulations of Emodepside (BAY 44-4400)” NCT06412926 ↗ |
| Known as | BAY 44-4400 | “A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside...” NCT03383614 ↗5“This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.” NCT02661178 ↗ “Single Doses of 2 Formulations of Emodepside (BAY 44-4400)” NCT06412926 ↗ “emodepside (BAY 44-4400)” NCT06800248 ↗ “emodepside (BAY 44-4400)” NCT06736691 ↗ “Emodepside (BAY 44-4400)” NCT03383523 ↗ |
| Known as | Emodepsida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104404 ↗ |
| Known as | Emodepside component of procox | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104404 ↗ |
| Known as | Emodepside component of profender | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104404 ↗ |
| Known as | PF 1022-221 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104404 ↗ |
| Modality | Small molecule | — CHEMBL2104404 ↗ |
| Route | Oral | “After Oral Dosing” NCT02661178 ↗ |